Fluvastatin

Generic Name
Fluvastatin
Brand Names
Lescol
Drug Type
Small Molecule
Chemical Formula
C24H26FNO4
CAS Number
93957-54-1
Unique Ingredient Identifier
4L066368AS
Background

Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prev...

Indication

To be used as an adjunct to dietary therapy to prevent cardiovascular events. May be used as secondary prevention in patients with coronary heart disease (CHD) to reduce the risk of requiring coronary revascularization procedures, for reducing progression of coronary atherosclerosis in hypercholesterolemic patients with CHD, and for the treatment of primary ...

Associated Conditions
Atherosclerosis, Heterozygous Familial Hypercholesterolemia (HeFH), Mixed Dyslipidemias, Primary Hypercholesterolemia, Revascularization procedures
Associated Therapies
-
Clinical Trials
Related News

Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients With Aortic Stenosis.

Phase 4
Terminated
Conditions
Aortic Valve Stenosis
Interventions
Drug: Fluvastatin
First Posted Date
2006-11-28
Last Posted Date
2019-06-07
Lead Sponsor
AORTICA Group
Target Recruit Count
164
Registration Number
NCT00404287
Locations
🇪🇸

Hospital Universitario de Salamanca, Salamanca, Spain

Cranoc Lipid Study in Renal Transplantation

Phase 2
Terminated
Conditions
Renal Transplantation
Interventions
Drug: Fluvastatin
First Posted Date
2005-09-22
Last Posted Date
2011-08-08
Lead Sponsor
University Hospital Schleswig-Holstein
Target Recruit Count
200
Registration Number
NCT00223041
Locations
🇩🇪

University of Schleswig-Holstein, Campus Kiel, Department of Nephrology, Kiel, Germany

Statins in Proteinuric Nephropathies

First Posted Date
2005-09-20
Last Posted Date
2010-04-28
Lead Sponsor
Mario Negri Institute for Pharmacological Research
Target Recruit Count
217
Registration Number
NCT00199927
Locations
🇮🇹

Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy

🇮🇹

Hospital "Casa Sollievo della Sofferenza" - Unit of Nephrology and Dialysis, San Giovanni Rotondo, Foggia, Italy

🇮🇹

Hospital "S.Giacomo Apostolo", Castelfranco Veneto, Treviso, Italy

and more 13 locations

Trial to Evaluate the Efficacy of Fluvastatin on Certain Markers

Phase 4
Completed
Conditions
Dyslipidemia
First Posted Date
2005-09-15
Last Posted Date
2017-02-23
Lead Sponsor
Novartis
Target Recruit Count
120
Registration Number
NCT00171262
Locations
🇪🇸

Novartis, Madrid, Spain

Statin Therapy in Asymptomatic Aortic Stenosis

Phase 2
Conditions
Aortic Valve Stenosis
First Posted Date
2005-09-15
Last Posted Date
2010-01-14
Lead Sponsor
University of Leipzig
Target Recruit Count
100
Registration Number
NCT00176410
Locations
🇩🇪

University of Leipzig - Heart Center, Leipzig, Saxony, Germany

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

First Posted Date
2005-09-15
Last Posted Date
2011-11-08
Lead Sponsor
Novartis
Target Recruit Count
84
Registration Number
NCT00171236
Locations
🇨🇭

Novartis, Basel, Switzerland

Fluvastatin in the Therapy of Acute Coronary Syndrome

Phase 4
Completed
Conditions
Coronary Disease
Myocardial Infarction
First Posted Date
2005-09-15
Last Posted Date
2010-07-16
Lead Sponsor
Novartis
Target Recruit Count
1000
Registration Number
NCT00171275
Locations
🇨🇿

Novartis, Praha, Czech Republic

Other Effects of Fluvastatin Are Investigated in Patients With Metabolic Syndrome

Phase 4
Completed
Conditions
Metabolic Syndrome
First Posted Date
2005-08-30
Last Posted Date
2017-02-23
Lead Sponsor
Novartis
Target Recruit Count
55
Registration Number
NCT00138528
Locations
🇩🇪

Novartis, Nürnberg, Germany

Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia

Phase 3
Completed
Conditions
Mixed Dyslipidemia
Hypercholesterolemia
First Posted Date
2005-08-29
Last Posted Date
2017-02-23
Lead Sponsor
Novartis
Target Recruit Count
325
Registration Number
NCT00136799
Locations
🇨🇳

Novartis, Shangai, China

Fluvastatin in Adults With Dislipidemia With History of Muscle Problems

Phase 4
Completed
Conditions
Dyslipidemia
First Posted Date
2005-07-29
Last Posted Date
2017-05-17
Lead Sponsor
Novartis
Target Recruit Count
218
Registration Number
NCT00125125
Locations
🇺🇸

Novartis, East Hanover, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy